Aptahem announces strengthened research results with Apta-1 from completed NHP study
Aptahem (publ) today announce positive final results from the exploratory sepsis study with non human primates, the NHP study. The new preclinical results continue to support Apta-1’s multifunctional drug candidate potential within the treatment of sepsis. The completed comprehensive study report contributes to further in-depth knowledge of Apta-1's mechanism of action and preliminary opens up new patent opportunities.The results of the NHP study have contributed to an increased understanding of the anticoagulant, anti-inflammatory and immunomodulatory effects that Apta-1 previously